- Conditions
- Heart Failure With Preserved Ejection Fraction
- Interventions
- JK07, Matching Placebo
- Drug
- Lead sponsor
- Salubris Biotherapeutics Inc
- Industry
- Eligibility
- 18 Years to 85 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 7
- States / cities
- Stanford, California • Boston, Massachusetts • Rochester, Minnesota + 4 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 106
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Heart Failure With Preserved Ejection Fraction
- Interventions
- IW-1973, Placebo Oral Tablet
- Drug
- Lead sponsor
- Akebia Therapeutics
- Industry
- Eligibility
- 45 Years and older
- Enrollment
- 196 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 57
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 45 more
- Conditions
- Heart Failure
- Interventions
- Ziltivekimab, Placebo
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 4,874 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 172
- States / cities
- Alexander City, Alabama • Fairhope, Alabama • Huntsville, Alabama + 141 more
- Conditions
- Heart Failure With Preserved Ejection Fraction (HFpEF), Heart Failure With Mildly Reduced Ejection Fraction (HFmrEF)
- Interventions
- Elecoglipron, Placebo
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 6,950 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 120
- States / cities
- Fairhope, Alabama • Anchorage, Alaska • Gilbert, Arizona + 105 more
- Conditions
- Heart Failure With Preserved Ejection Fraction
- Interventions
- Dapagliflozin, Placebo
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Heart Failure Preserved Ejection Fraction
- Interventions
- Coronary Sinus Reducer
- Device
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Heart Failure With Preserved Ejection Fraction
- Interventions
- m-health cardiac rehabilitation
- Other
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 69 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Heart Failure With Preserved Ejection Fraction (HFpEF)
- Interventions
- Dapagliflozin, Placebo
- Drug · Other
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 40 Years to 150 Years
- Enrollment
- 504 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 25
- States / cities
- Alexander City, Alabama • Fort Payne, Alabama • Beverly Hills, California + 21 more
- Conditions
- Heart Failure With Preserved Ejection Fraction (HFpEF)
- Interventions
- STM01
- Drug
- Lead sponsor
- Secretome Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025
- U.S. locations
- 2
- States / cities
- Chicago, Illinois • Dallas, Texas
- Conditions
- Heart Failure With Preserved Ejection Fraction
- Interventions
- 68Ga-FAPI (gallium-68-labeled fibroblast activation protein inhibitor)
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Heart Failure, Diastolic, Obesity
- Interventions
- dietary, aerobic and resistance training, dietary, and aerobic exercise
- Behavioral
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 60 Years and older
- Enrollment
- 88 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2021
- U.S. locations
- 1
- States / cities
- Winston-Salem, North Carolina
- Conditions
- Heart Failure With Preserved Ejection Fraction
- Interventions
- EDG-15400 25 mg, Placebo to match EDG-15400 25 mg or 50 mg, EDG-15400 50 mg
- Drug
- Lead sponsor
- Edgewise Therapeutics, Inc.
- Industry
- Eligibility
- 30 Years to 84 Years
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 25
- States / cities
- Birmingham, Alabama • Beverly Hills, California • San Diego, California + 20 more
- Conditions
- Heart Failure
- Interventions
- Empagliflozin, Placebo
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 315 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 43
- States / cities
- Mobile, Alabama • Saraland, Alabama • Huntington Beach, California + 39 more
- Conditions
- Heart Failure With Preserved Ejection Fraction
- Interventions
- PeriCut Catheter System performs minimally invasive pericardiotomy
- Device
- Lead sponsor
- Heart Failure Solutions, Inc.
- Industry
- Eligibility
- 30 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Heart Failure, Heart Failure With Reduced Ejection Fraction (HFrEF), Heart Failure With Preserved Ejection Fraction (HFPEF), Iron Deficiency, Iron-deficiency Anemia (IDA)
- Interventions
- Ferric Carboxymaltose, Ferrous Sulfate
- Drug
- Lead sponsor
- Syed Hamza Mufarrih
- Other
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Bowling Green, Kentucky
- Conditions
- Heart Failure With Preserved Ejection Fraction, Chronic Kidney Diseases
- Interventions
- MANP, Sacubitril/Valsartan, Oral Placebo, Injection Placebo
- Drug
- Lead sponsor
- Horng Chen
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Heart Failure
- Interventions
- Static Handgrip, Dexmedetomidine, Glycopyrrolate, Isoproterenol
- Other · Drug
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2017
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Heart Failure With Preserved Ejection Fraction, Venous Disease
- Interventions
- Not listed
- Lead sponsor
- Prairie Education and Research Cooperative
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Springfield, Illinois
- Conditions
- Heart Failure With Normal Ejection Fraction
- Interventions
- Anakinra, Placebo
- Drug
- Lead sponsor
- Virginia Commonwealth University
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 1
- States / cities
- Richmond, Virginia
- Conditions
- Heart Failure With Preserved Ejection Fraction, Healthy
- Interventions
- MRI (cardiac) off-label use gadolinium contrast (IND exempt), MRI (cardiac)
- Diagnostic Test
- Lead sponsor
- University of California, Los Angeles
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2022
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Heart Failure With Preserved Ejection Fraction
- Interventions
- PL-3994 Aqueous Intravenous Solution Dose Ascention, PL-3994 Aqueous Intravenous Solution Single Dose
- Drug
- Lead sponsor
- Palatin Technologies, Inc
- Industry
- Eligibility
- 21 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 1
- States / cities
- Evanston, Illinois
- Conditions
- Heart Failure With Preserved Ejection Fraction
- Interventions
- Sotagliflozin, Placebo
- Drug
- Lead sponsor
- Juan Badimon
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 88 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Pulmonary Hypertension Associated With HFpEF
- Interventions
- TNX-103, Placebo
- Drug
- Lead sponsor
- Tenax Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 540 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 46
- States / cities
- Alexander City, Alabama • Tucson, Arizona • Sacramento, California + 40 more
- Conditions
- Heart Failure With Preserved Ejection Fraction and Pulmonary Vascular Disease
- Interventions
- macitentan 10 mg
- Drug
- Lead sponsor
- Actelion
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 91 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 11
- States / cities
- Littleton, Colorado • Chicago, Illinois • Iowa City, Iowa + 8 more